BrainsWay Accelerates International Expansion in India

BURLINGTON, Mass. and JERUSALEM, July 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the expanded market penetration of its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology in India. After the most recent in a series of successive multisystem orders, Asha Neuromodulation Clinics (ANC) and its affiliates will own 25 Deep TMS systems, substantially increasing access to BrainsWay’s patented technology for mental health patients suffering from a range of conditions including , obsessive-compulsive disorder (), and .

“We are pleased that our unique form of therapy is gaining real traction in India,” said Hadar Levy, Chief Executive Officer of BrainsWay. “This is further proof of BrainsWay’s strategic commitment to expanding its international footprint, and allows us the ability to make a true difference in the lives of patients in the world’s most populous country. We are proud to partner with the ANC team in making this shared vision a reality.”

“At ANC, we understand the challenges of leading a fast-paced life and the need for better outcomes in mental health care delivery," said Dr. M.S. Reddy, Director of ANC. "That is why we are working with BrainsWay to offer the most advanced therapeutic solution available in the industry throughout the country, including at our new flagship clinic in Gachibowli, as well as at Asha Hospitals in Hyderabad, Bengaluru, Vizag, Mysuru, Vijayawada, Guntur, Chandigarh, and New Delhi.”

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit .

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The commercial events described herein may not necessarily correlate with financial results within any time periods expressly or implicitly attributed to such events. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:

BrainsWay: 

Ido Marom 

Chief Financial Officer 

844-386-7001 ext. 5

 

Investors: 

Brian Ritchie

LifeSci Advisors

646-889-1200

Media Contact: 

Chris Boyer

978-677-1777